USA flag logo/image

An Official Website of the United States Government

NOVEL PHARMACOTHERAPIES FOR ALCOHOLISM, TOPIC #4409/24/2012 - 03/23/2013

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
N43AA120010
Solicitation Year:
2012
Solicitation Topic Code:
NIAAA
Solicitation Number:
Small Business Information
NAPROGENIX, INC
KTRDC - U.K. - AgTecc Laboratories Lexington, KY 40546-0236
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: NOVEL PHARMACOTHERAPIES FOR ALCOHOLISM, TOPIC #4409/24/2012 - 03/23/2013
Agency: HHS
Contract: N43AA120010
Award Amount: $149,697.00
 

Abstract:

Alcoholism is a complex condition in which there are many potential molecular and therapeutic targets for pharmacotherapy. This fast track SBIR contract aims to investigate compounds targeted on the glutamate/NMDA receptor (NMDAR) and the nicotinic receptor for acetylcholine (nicAChR). These targets have direct relevance to several of the major therapeutic targets including detoxification of acute withdrawal, neurotoxicity, relapse, organ damage, co-morbid neuropathic pain, and co-morbid drug abuse (including smoking). Naprogenix first identifies synthetic drugs or plant metabolites by high throughput pharmacological screening, prioritizing lead compounds which have valuable multifunctionality. Leads are then tested in whole animal screens and models reflecting different specific aspects of alcoholism and the most promising are optimized by synthetic modification, or by a novel plant genomic approach. Phase 1 of this fast track proposal is to complete preliminary studies at the molecular level on the4 current best therapeutic candidates (2 synthetics and 2 natural products), and to prepare sufficient quantities of these for cellular studies and whole animal evaluation in phase 2. Also during phase 2, the company, with the National Institute on AlcoholAbuse and Alcoholism (NIAAA), will contact major pharmaceutical and nutritional companies to explore the further development of these compounds as medications or nutraceuticals.

Principal Investigator:

John Littleton
859-257-1127
JLITTLET@UKY.EDU

Business Contact:

John Littleton
859-257-1127
JLITTLET@UKY.EDU
Small Business Information at Submission:

NAPROGENIX, INC
Naprogenix, Inc. KTRDC - U.K. - AgTecc Laboratories Lexington, KY 40546-0236

EIN/Tax ID: 571144999
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No